Sulfadiazine modified PDMS as a model material with the potential for the mitigation of posterior capsule opacification (PCO)

Colloids and Surfaces B: Biointerfaces

Volumn 111, Issue , 2013, Pages 15-23

  Amoozgar, Bahram ^a   Morarescu, Diana ^a   Sheardown, Heather ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Epithelial to mesenchymal transition (EMT); Intraocular lens (IOL); Matrix metalloproteinase (MMP); Posterior capsule opacification (PCO); Transforming growth factor beta 2 (TGF 2)

Indexed keywords

EPITHELIAL TO MESENCHYMAL TRANSITIONS; EXTRACELLULAR MATRIX COMPONENTS; MATRIX METALLOPROTEINASES; POLYDIMETHYLSILOXANE PDMS; POLYETHYLENE GLYCOL (PEG); POSTERIOR CAPSULE OPACIFICATION; SURFACE CHARACTERIZATION; TRANSFORMING GROWTH FACTOR BETA 2;

CELL CULTURE; ENZYME INHIBITION; INTRAOCULAR LENSES; MICROCHANNELS; PROTEINS;

SILICONES;

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN; DIMETICONE; FIBRONECTIN; LAMININ; MACROGOL; MATRIX METALLOPROTEINASE INHIBITOR; RHO FACTOR; SULFADIAZINE; TRANSFORMING GROWTH FACTOR BETA2; ACTA2 PROTEIN, HUMAN; ACTIN; MACROGOL DERIVATIVE; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; WATER;

ARTICLE; CATARACT; CELL DIFFERENTIATION; CELL MIGRATION; CHEMICAL MODIFICATION; CONTROLLED STUDY; EPITHELIUM CELL; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; IN VIVO STUDY; INFANT; LENS EPITHELIUM; PRIORITY JOURNAL; PROTEIN SYNTHESIS; SURFACE PROPERTY; CAPSULE OPACIFICATION; CELL COMMUNICATION; CELL LINE; CELL MOTION; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; INFRARED SPECTROSCOPY; LENS; MASS SPECTROMETRY; METABOLISM; PATHOLOGY; X RAY PHOTOELECTRON SPECTROSCOPY;

ACTINS; CAPSULE OPACIFICATION; CELL COMMUNICATION; CELL LINE; CELL MOVEMENT; CELL SURVIVAL; COLLAGEN; DIMETHYLPOLYSILOXANES; FIBRONECTINS; HUMANS; INFANT; LAMININ; LENS, CRYSTALLINE; MASS SPECTROMETRY; PHOTOELECTRON SPECTROSCOPY; POLYETHYLENE GLYCOLS; RHO GTP-BINDING PROTEINS; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SULFADIAZINE; SURFACE PROPERTIES; WATER;

EID: 84879476507     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2013.05.002     Document Type: Article

References (45)

1. Hollick E. Cataract: mission statement. Evidence-based Ophthalmology 2008, 219-220. BMJ Publishing Group.
2. Danysh B.P., Duncan M.K. The lens capsule. Exp. Eye Res. 2009, 88:151-164.
3. Whikehart D.R. Biochemistry of the Eye 2003, Butterworth-Heinemann, Boston. 2nd ed.
4. Beebe D.C. Maintaining transparency: a review of the developmental physiology and pathophysiology of two avascular tissues. Semin. Cell Dev. Biol. 2008, 19:125-133.
5. Walker T.D. Pharmacological attempts to reduce posterior capsule opacification after cataract surgery-a review. Clin. Exp. Ophthalmol. 2008, 36:883-890.
6. Wormstone I.M., Wang L., Liu C.S. Posterior capsule opacification. Exp. Eye Res. 2009, 88:257-269.
7. Beers M.H., Porter R.S., Jones T.V. The Merck Manual Diagnosis and Therapy 2006, Whitehouse Station, New Jersey. 18th ed.
8. Saika S. Relationship between posterior capsule opacification and intraocular lens biocompatibility. Prog. Retin. Eye Res. 2004, 23:283-305.
9. Oshika T., Nagata T., Ishii Y. Adhesion of lens capsule to intraocular lenses of polymethylmethacrylate, silicone, and acrylic foldable materials: an experimental study. Br. J. Ophthalmol. 1998, 82:549-553.
10. Apple D.J., Ram J., Foster A., Peng Q. Posterior capsule opacification (secondary cataract). Surv. Ophthalmol. 2000, 45(Suppl. 1):S100-S130.
11. Ratner B.D., Hoffman A.S., Schoen F.J., Lemons J.E. Biomaterials Science: An Introduction to Materials in Medicine 1996, Academic Press, San Diego.
12. Awasthi N., Guo S., Wagner B.J. Posterior capsular opacification: a problem reduced but not yet eradicated. Arch. Ophthalmol. 2009, 127:555-562.
13. Dewey S. Posterior capsule opacification. Curr. Opin. Ophthalmol. 2006, 17:45-53.
14. Wormstone I.M. Posterior capsule opacification: a cell biological perspective. Exp. Eye Res. 2002, 74:337-347.
15. Saika S., Yamanaka O., Sumioka T., Miyamoto T., Miyazaki K., Okada Y., Kitano A., Shirai K., Tanaka S., Ikeda K. Fibrotic disorders in the eye: targets of gene therapy. Prog. Retin. Eye Res. 2008, 27:177-196.
16. Li J., Chen J., Kirsner R. Pathophysiology of acute wound healing. Clin. Dermatol. 2007, 25:9-18.
17. Meacock W.R., Spalton D.J., Stanford M.R. Role of cytokines in the pathogenesis of posterior capsule opacification. Br. J. Ophthalmol. 2000, 84:332-336.
18. Kalluri R., Weinberg R.A. The basics of epithelial-mesenchymal transition. J. Clin. Invest. 2009, 119:1420-1428.
19. Zeisberg M., Neilson E.G. Biomarkers for epithelial-mesenchymal transitions. J. Clin. Invest. 2009, 119:1429-1437.
20. Lee J.M., Dedhar S., Kalluri R., Thompson E.W. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J. Cell Biol. 2006, 172:973-981.
21. Chong C.C., Stump R.J., Lovicu F.J., McAvoy J.W. TGFβ promotes Wnt expression during cataract development. Exp. Eye Res. 2009, 88:307-313.
22. Banh A., Deschamps P.A., Gauldie J., Overbeek P.A., Sivak J.G., West-Mays J.A. Lens-specific expression of TGFβ induces anterior subcapsular cataract formation in the absence of Smad3. Invest. Ophthalmol. Vis. Sci. 2006, 47:3450-3460.
23. Gotoh N., Perdue N.R., Matsushima H., Sage E.H., Yan Q., Clark J.I. An in vitro model of posterior capsular opacity: SPARC and TGF-beta2 minimize epithelial-to-mesenchymal transition in lens epithelium. Invest. Ophthalmol. Vis. Sci. 2007, 48:4679-4687.
24. Banh A., Deschamps P.A., Vijayan M.M., Sivak J.G., West-Mays J.A. The role of Hsp70 and Hsp90 in TGF-beta-induced epithelial-to-mesenchymal transition in rat lens epithelial explants. Mol. Vis. 2007, 13:2248-2262.
25. Lovicu F.J., Schulz M.W., Hales A.M., Vincent L.N., Overbeek P.A., Chamberlain C.G., McAvoy J.W. TGFbeta induces morphological and molecular changes similar to human anterior subcapsular cataract. Br. J. Ophthalmol. 2002, 86:220-226.
26. Lois N., Taylor J., McKinnon A.D., Smith G.C., van't Hof R., Forrester J.V. Effect of TGF-beta2 and anti-TGF-beta2 antibody in a new in vivo rodent model of posterior capsule opacification. Invest. Ophthalmol. Vis. Sci. 2005, 46:4260-4266.
27. Wormstone I.M., Tamiya S., Anderson I., Duncan G. TGF-beta2-induced matrix modification and cell transdifferentiation in the human lens capsular bag. Invest. Ophthalmol. Vis. Sci. 2002, 43:2301-2308.
28. Wormstone I.M., Anderson I.K., Eldred J.A., Dawes L.J., Duncan G. Short-term exposure to transforming growth factor beta induces long-term fibrotic responses. Exp. Eye Res. 2006, 83:1238-1245.
29. Dawes L.J., Elliott R.M., Reddan J.R., Wormstone Y.M., Wormstone I.M. Oligonucleotide microarray analysis of human lens epithelial cells: TGFbeta regulated gene expression. Mol. Vis. 2007, 13:1181-1197.
30. West-Mays J.A., Pino G. Matrix metalloproteinases as mediators of primary and secondary cataracts. Expert Rev. Ophthalmol. 2007, 2:931-938.
31. Zelenka P.S., Arpitha P. Coordinating cell proliferation and migration in the lens and cornea. Semin. Cell Dev. Biol. 2008, 19:113-124.
32. Li J.H., Wang N.L., Wang J.J. Expression of matrix metalloproteinases of human lens epithelial cells in the cultured lens capsule bag. Eye 2008, 22:439-444.
33. Wong T.T., Daniels J.T., Crowston J.G., Khaw P.T. MMP inhibition prevents human lens epithelial cell migration and contraction of the lens capsule. Br. J. Ophthalmol. 2004, 88:868-872.
34. Morarescu D., West-Mays J.A., Sheardown H.D. Effect of delivery of MMP inhibitors from PDMS as a model IOL material on PCO markers. Biomaterials 2010, 31:2399-2407.
35. Dwivedi D.J., Pino G., Banh A., Nathu Z., Howchin D., Margetts P., Sivak J.G., West-Mays J.A. Matrix metalloproteinase inhibitors suppress transforming growth factor-beta-induced subcapsular cataract formation. Am. J. Pathol. 2006, 168:69-79.
36. Tamura Y., Watanabe F., Nakatani T., Yasui K., Fuji M., Komurasaki T., Tsuzuki H., Maekawa R., Yoshioka T., Kawada K., Sugita K., Ohtani M. Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives. J. Med. Chem. 1998, 41:640-649.
37. Park H.I., Jin Y., Hurst D.R., Monroe C.A., Lee S., Schwartz M.A., Sang Q.X. The intermediate S1' pocket of the endometase/matrilysin-2 active site revealed by enzyme inhibition kinetic studies, protein sequence analyses, and homology modeling. J. Biol. Chem. 2003, 278:51646-51653.
38. McCauley R.L., Linares H.A., Pelligrini V., Herndon D.N., Robson M.C., Heggers J.P. In vitro toxicity of topical antimicrobial agents to human fibroblasts. J. Surg. Res. 1989, 46:267-274.
39. Leitch I.O., Kucukcelebi A., Robson M.C. Inhibition of wound contraction by topical antimicrobials. Aust. N.Z. J. Surg. 1993, 63:289-293.
40. Shanmugasundaram N., Uma T.S., Ramyaa Lakshmi T.S., Babu M. Efficiency of controlled topical delivery of silver sulfadiazine in infected burn wounds. J. Biomed. Mater. Res. A 2009, 89:472-482.
41. Mikhail A.S., Jones K.S., Sheardown H. Dendrimer-grafted cell adhesion peptide-modified PDMS. Biotechnol. Progr. 2008, 24:938-944.
42. Chen H., Brook M.A., Sheardown H.D., Chen Y., Klenkler B. Generic bioaffinity silicone surfaces. Bioconjugate Chem. 2006, 17:21-28.
43. Klenkler B.J., Dwivedi D., West-Mays J.A., Sheardown H. Corneal epithelial cell adhesion and growth on EGF-modified aminated PDMS. J. Biomed. Mater. Res. A 2010, 93:1043-1049.
44. Chen H., Brook M.A., Sheardown H. Silicone elastomers for reduced protein adsorption. Biomaterials 2004, 25:2273-2282.
45. Nathu Z., Dwivedi D.J., Reddan J.R., Sheardown H., Margetts P.J., West-Mays J.A. Temporal changes in MMP mRNA expression in the lens epithelium during anterior subcapsular cataract formation. Exp. Eye Res. 2009, 88:323-330.